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Eradication of Hepatitis C Infection: The
Importance of Targeting People Who Inject Drugs
H
epatitis C virus (HCV) affects 170 million
people worldwide and causes significant mor-
bidity and mortality.1 In high-income coun-
tries, people who inject drugs (PWID) are at greatest
risk of HCV infection.2 Until recently HCV eradica-
tion seemed unlikely, but recent advances in HCV treat-
ment and improved understanding of the effectiveness
of harm-reduction intervention effectiveness give reason
for optimism. Current HCV treatments can cure 75%
of patients and new drugs will further improve effective-
ness (over 90% cure) and improve tolerability.3 If HCV
treatment can be delivered effectively to those at highest
risk of onward transmission, significant reductions in
future HCV cases are possible. The feasibility of disease
eradication must be assessed on both scientific criteria
(e.g., epidemiological susceptibility, effective and practi-
cal intervention available, and demonstrated feasibility
of elimination) and political criteria (e.g., burden of dis-
ease, cost of intervention).4 With effective, curative
treatment now available, HCV meets these criteria.
Importance of Targeting PWID
To achieve eradication, public health efforts must
focus on PWID, the key drivers of HCV transmission.
A sustained, multipronged approach could substan-
tially reduce HCV infection in PWID over the next
10-20 years through a focus on HCV treatment as
prevention, meaning improved access to more effective
and well-tolerated HCV treatment. Other major ele-
ments include increasing coverage of opiate substitu-
tion therapy (OST), needle and syringe programs
(NSPs), and regular HCV screening and counseling.
PWID are highly marginalized, so effective engage-
ment and inclusion in strategy development are critical
to HCV eradication. To date, health services have been
unsuccessful in channeling PWID into HCV treat-
ment, despite evidence of willingness to be treated5
and treatment success.6
HCV Treatment as Prevention
For the past decade HCV treatment has mostly
involved pegylated interferon and ribavirin (PEG/RBV);
however, trials of direct-acting antivirals (DAAs) show
increased rates of cure, improved tolerability, and reduced
duration of treatment.3,7,8 The first NS3 protease inhibi-
tors, boceprevir and telaprevir, used in combination with
PEG/RBV, have already improved outcomes, with up to
75% of patients chronically infected with HCV genotype-
1 being cured.3 Emerging therapies that include next-
generation NS3 protease inhibitors, NS5A inhibitors, and
NS5B polymerase inhibitors show great promise.7,8 An
interferon-free 12-week DAA regimen with single daily
dosing and over 90% cure is a real possibility.3
Highly effective and tolerable HCV therapies will
make treatment as prevention feasible. This strategy
will require targeting PWID, few of whom undergo
HCV treatment despite increasing evidence of success.6
The rarity of PWID undergoing treatment relates to
concerns about interferon toxicity and RBV teratoge-
nicity and unsubstantiated concerns about PWID
compliance and high reinfection rates. Apart from
managing adverse side effects, we know little about
interventions that improve HCV treatment compli-
ance.9 However, increasing evidence shows that PWID
are compliant when treated with PEG/RBV,10 and
compliance can only rise with improved treatment tol-
erability. Similarly, most evidence suggests HCV rein-
fection following treatment remains low.11
Models developed by Martin et al.12 suggest that
treating a relatively small proportion of PWID could
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significantly reduce HCV prevalence over 15 years,
with the impact varying depending on the number
treated, the background HCV prevalence, treatment
efficacy, and the speed of treatment scale-up (Fig. 1).
Estimated HCV prevalence halved when treatment was
scaled up to 15, 40, or 76 per 1,000 PWID annually
in Edinburgh (Scotland), Melbourne (Australia), and
Vancouver (Canada), respectively, using DAAs. Cur-
rent estimated HCV prevalence in PWID in those
three jurisdictions is 25%, 50%, and 65%, respectively.
Recent modeling of PWID in Vietnam also revealed
treatment impact on HCV prevalence.13
Harm Reduction to Reduce HCV
Transmission
Prevention of HCV transmission is critically impor-
tant for HCV eradication. Harm-reduction strategies
for PWID, notably OST and NSPs, have been partially
effective in reducing HCV transmission in PWID,14
although poor coverage has limited their impact.15 A
recent study estimated that NSPs directly averted
97,000 (50%) new HCV infections in Australia dur-
ing 2000-2009.14 Modeling by Vickerman et al.16 sug-
gests that, in a setting where HCV prevalence is 40%,
scaling OST/NSP coverage up from 0% to 20%,
40%, and 60% can reduce HCV prevalence over 10
years by 13%, 24%, and 33%, respectively. However,
further increments in coverage produce only marginal
improvements,16 suggesting that complementary strat-
egies are required to substantially reduce HCV
prevalence.
Treatment Access and Cost
PWID are highly marginalized and few receive HCV
treatment despite increasing evidence that treatment
works.6 Effective engagement with PWID is critical to
HCV eradication. Integrated multidisciplinary
approaches that include clinicians, nurses and other
support services, located in community-based settings
or OST clinics, can increase HCV assessment and treat-
ment.17 Infrastructure, workforce capacity and educa-
tion programs focused on PWIDs’ needs are needed for
timely and effective strategy implementation; currently,
many primary care clinicians and health service staff
know little about HCV assessment and care.18
Current HCV treatment is expensive and the cost
of scale-up with more expensive therapies will be con-
siderable. Visconti et al.’s19 modeling found that treat-
ing both current and former PWID for HCV using
standard PEG/RBV was cost-effective. Martin et al.’s20
model included the broader public health benefit of
reducing HCV prevalence, and showed antiviral treat-
ment for PWID saved £521 and £2,539 per quality-
adjusted life year (QALY) when baseline HCV preva-
lence was 20% and 40%, respectively, compared with
no treatment, well below generally accepted thresholds
for cost-effective interventions. Despite the cost-
effectiveness of treating PWID, the actual costs of
HCV treatment, particularly DAAs, will challenge gov-
ernments in both developed and resource-limited set-
tings; nonetheless, the models suggest standard HCV
therapy still has considerable benefits.
Injecting Networks
Most models assume homogeneous mixing of PWID
with all other PWID in the population; few consider the
impact of PWIDs’ social and injecting networks on
HCV transmission or clearance. A recent HCV PWID
network model derived from empirical data indicated
that injecting networks substantially impact transmis-
sion.21 Further modeling suggested that treating PWIDs
and their immediate contacts simultaneously (as
opposed to ad hoc treatment) reduces the overall num-
ber of PWID needing treatment, reducing long-term
HCV prevalence and treatment costs.
HCV Vaccination
Candidate vaccines designed to prevent initial infec-
tion, reduce viral persistence in acute infection, or lead
to sustained virological response (SVR) in chronic
infection are in phase 2 and 3 trials.22 However, expe-
rience with the highly effective hepatitis B vaccine
Fig. 1. Annual scaled-up treatment rate required to reduce preva-
lence by 1/4, 1/2, or 3/4 in Edinburgh, Melbourne, and Vancouver
within 15 years (by 2027). Bars (and numbers) indicate the mean
value, with whiskers representing the 95% credibility interval.
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suggests uptake among PWID may be low.23 Hence,
an HCV vaccine will be just one component of an
HCV eradication strategy.
In conclusion, eradicating HCV in PWID is
ambitious but, based on the criteria for assessing
disease eradicability,4 achievable (Table 1). Treatment
costs will be substantial and recruiting sufficient
PWID to treatment programs challenging. However,
scale-up of HCV diagnosis and treatment with new
highly efficacious and tolerable drugs, plus effective
and relatively inexpensive harm reduction and pre-
vention approaches, will considerably reduce HCV
prevalence. Eradicating HCV needs a sustained,
focused and multipronged approach; the time to
start is now.
Author Roles: M.H. wrote the first draft of the arti-
cle. All authors reviewed and edited the primary and
subsequent revised versions of the article.
MARGARET HELLARD1-3
JOSEPH S. DOYLE1-4
RACHEL SACKS-DAVIS1,3
ALEXANDER J. THOMPSON4,5
EMMA MCBRYDE1,4
1Centre for Population Health,
Burnet Institute,
Melbourne, Victoria, Australia
2Infectious Diseases Unit,
The Alfred Hospital,
Melbourne, Victoria, Australia
3Department of Epidemiology and Preventive
Medicine, Monash University, Melbourne,
Victoria, Australia
4Victorian Infectious Disease Service,
Royal Melbourne Hospital, Parkville,
Victoria, Australia
5Department of Gastroenterology, St Vincent’s
Hospital, Melbourne, Victoria, Australia
Table 1. Assessing HCV Eradicability
Criteria for Assessing Eradicability Application of the Criteria to HCV
Scientific Feasibility4 Facilitators Challenges
Epidemiologic susceptibility (e.g., no nonhuman
reservoir, ease of spread, naturally induced
immunity, ease of diagnosis)
No nonhuman reservoir Limited naturally induced immunity
Transmission limited to specific risk groups
and preventable through behavior change.
Simple diagnostic test
Effective, practical intervention available
(e.g., vaccine, curative treatment)
Curative treatments with improving efficacy
and tolerability
No current effective vaccine
Demonstrated feasibility of elimination
(e.g., documented elimination
from island or other geographic unit)
Mathematical modeling demonstrating
a reduction in prevalence and incidence
No actual demonstrated
feasibility of elimination
Political will and popular support4
Perceived burden of the disease
(e.g., extent, deaths, other effects;
relevance to rich and poor countries)
Globally it is recognized that HCV morbidity
and mortality are increasing as are the
associated costs of managing chronic infection
There is significant stigma against
people who inject drugs, the
group most affected by HCV
Growing political will to address HCV burden
in developed countries (e.g., birth-cohort
screening programs in USA)
Expected cost of eradication Modeling suggesting reducing HCV
prevalence and incidence through
treatment is cost effective
Modeling suggesting reducing HCV
prevalence and incidence through
treatment is expensive
Synergy of eradication efforts with other
interventions (e.g., potential for added
benefits or savings)
Strategies are available to reduce the cost
of eradication e.g. using a contact tracing
(network) approach for HCV treatment
Harm reduction strategies are inexpensive and
contribute to reductions in HCV burden – needle
and syringe programs, OST
Need for eradication rather than control Despite the short-term expense of eradication it would
lead to long-term savings. If eradicated the costs
associated with HCV screening, vaccination,
treatment, and management of disease progression
would be reduced
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